Seattle Genetics halted all clinical trials of its vadastuximab talirine due to higher incidents of death associated with the treatment for AML patients.

In meeting with industry analysts, J&J indicated it expects to have 10 new products approved between 2017 and 2021 that have blockbuster potential.

The U.S. FDA approved Novartis AG’s Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders.

Cyclacel Pharmaceuticals Inc. said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study.

Seattle Genetics said four people died in trials testing its experimental cancer drug, prompting the U.S. FDA to impose a clinical hold on several early-stage studies.

Helsinn Group and MEI Pharma inked an exclusive licensing, development and commercialization deal to develop and market Pracinostat to treat AML.

Celator Pharmaceuticals Inc on Monday said its Vyxeos treatment helped older high-risk patients with a deadly form of leukemia live longer than those who received the standard of care regimen in a late stage clinical trial, sending its stock price soaring. Celator shares jumped to $9 in extended trading from a Nasdaq close at $1.68. […]

Novartis received breakthrough therapy designation from the U.S. Food and Drug Administration for an investigational treatment for newly-diagnosed FLT3-mutated acute myeloid leukemia, the Swiss drugmaker said on Friday. Patients who received PKC412, also called midostaurin, combined with standard induction and consolidation chemotherapy experienced what Novartis called “a significant improvement in overall survival”. With the announcement, […]

Novartis’ phase III study for its acute myeloid leukemia (AML) drug showed it improved overall survival by 23 percent for patients with FLT3 mutations, the Swiss drugmaker said on Sunday.   Basel-based Novartis said the study was the first large controlled trial to show overall survival benefit in FLT3-mutated AML, and that worldwide regulatory submissions […]

U.S. drugmaker Pfizer and France’s Servier have snapped up rights to a promising cell therapy developed by French biotech firm Cellectis to fight blood cancers. The so-called CAR T cell technology used by Cellectis involves reprogramming immune system cells to hunt out cancer. The “off-the-shelf” approach recently proved very successful in the case of a […]